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Abstract
United Nation’s Sustainable Development Goals and the World Health Organization’s Global 
Monitoring Framework support a strong global commitment to reducing the high burden of 
cervical and breast cancers among low- and middle-income countries. Strategies include 
vaccination, screening, and early diagnosis. Population-based surveys, such as those conducted by 
the Demographic and Health Surveys (DHS) Program, can collect the information needed to guide 
cancer control efforts in a standardized comparable manner. We identified and evaluated the 
breadth of breast and cervical cancer screening information that was collected by the DHS from 
1984 through 2015. Then, we determined if these surveys currently provide the specific and 
measurable data about both the quantity and quality of cancer screening needed to guide national 
efforts to reduce the overall effects of cervical and breast cancers. We searched the DHS website to 
identify surveys conducted between the start of the DHS Program in 1984 and November 2015 
that included questions about breast and cervical cancer screening. The relevant questions were 
extracted from the questionnaire, translated into English, and grouped by themes. Of the 90 
countries where DHS surveys have been implemented, cervical cancer screening questions were 
included in 22 countries (24.4%) and breast cancer screening questions in 18 countries (20.0%). 
The common themes identified were disease knowledge, screening knowledge, screening practice, 
and screening outcomes. Most countries with survey questionnaires available for review addressed 
at least one aspect of screening practice (88.9% of cervical and 87.5% of breast), although few 
countries queried knowledge and outcomes. Questions that assess varied aspects of breast and 
cervical cancer screening have been incorporated into relatively few DHS surveys. The themes 
identified could guide the design of a standard set of questions for use in future population-based 
surveys and enable evaluation beyond the existence of screening, which would include assessment 
of the quality and impact of cervical and breast cancer screening.
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Introduction
Cervical and breast cancers greatly affect low- and middle-income countries.1 Cervical 
cancer is the fourth most common cancer diagnosis among women globally; 85% of cervical 
cancer cases and 87% of deaths occur in less developed regions.2 Breast cancer is the most 
common cancer among women, accounting for 25% of all cancers diagnosed among women 
worldwide; a slight majority of these cases occur among less developed regions, with more 
favorable survival rates in developed regions.2 The overall effects of cervical cancer can be 
reduced through vaccination against the human papillomavirus (HPV), screening for 
precancers and cancers, and treatment of precancerous lesions.3 Approaches to reduce the 
effects of breast cancer include early awareness and care seeking, clinical breast 
examination, and screening with mammography, depending on country priorities and 
resources.4
The World Health Organization (WHO) recommends a life course approach to global 
cervical cancer control.3 This approach includes HPV vaccination for boys and girls aged 9–
13 years, a minimum of once in a lifetime cervical cancer screening for women aged 30–49 
years, treatment of precancers and cancers, and access to appropriate palliative care, as 
needed. Cervical cancer screening can include HPV testing, visual inspection methods, and 
cytology, where available. The Breast Health Global Initiative has developed evidence-
based, culturally appropriate, and economically feasible screening guidelines to improve 
breast cancer outcomes.5 The WHO position article on mammography screening addresses 
uncertainties in the evidence base surrounding benefits and harms, and offers specific 
screening recommendations by age and resource setting, ranging from clinical breast 
examination to organized, biennial, population-based, mammography screening programs, 
when the necessary health system requirements exist and in the context of shared decision 
making.4 Many countries have created national policies and guidelines for how to implement 
recommendations for breast and cervical cancer screening specific to their populations,6 and 
many countries are taking steps toward establishing nationwide organized screening for 
cervical and breast cancers.7
The WHO 2013 Comprehensive Global Monitoring Framework includes 25 indicators that 
countries can use to monitor their implementation of national strategies to prevent and 
control noncommunicable diseases (NCDs).8 The most applicable indicator in the 
framework assesses the proportion of women screened for cervical cancer. Other 
nonscreening breast and cervical cancer indicators include the availability of the vaccine 
against HPV; availability of cancer medicines, technologies, and palliative care; proportion 
of premature deaths from cancer; and cancer incidence by type. The 17 UN sustainable 
development goals (SDG) (also known as Transforming Our World: The 2030 Agenda for 
Sustainable Development) represent a global commitment to transform our world in the 
areas of poverty reduction, prosperity, and health; the focus of SDG 3 is the assurance of 
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health and well-being across the lifespan, with 13 specific targets.9 The most relevant targets 
for cervical and breast cancer control address access to essential health services, including 
medicines and vaccines, and a one-third reduction in premature deaths from NCDs by 2030.
High-quality behavioral and risk factor surveillance data are necessary to guide and evaluate 
national cancer control programs and early detection efforts; however, these data are not yet 
available in many countries. Population-based surveys can collect this information in a 
standardized comparable manner; however, standardized and cognitively tested questions 
about cervical and breast cancers are not currently available. Examples of survey tools that 
can be used to assess behaviors and risk factors for cancer include the WHO STEPwise 
approach to NCD risk factor surveillance (STEPS) and the Demographic and Health Surveys 
(DHS) Program, supported by the U.S. Agency for International Development 
(USAID).10,11
More than 300 DHS surveys have been completed in 90 low- or middle-income countries 
since 1985, with the goal of compiling nationally representative data about indicators 
relevant to local population, health, and nutrition for use in policy and program planning, 
implementation, and evaluation11 (Fig. 1). The DHS Program supports population-based 
surveys covering topics, such as maternal and child health, HIV/AIDS, malaria, nutrition, 
women’s empowerment, fertility, and family planning. The program is funded by USAID 
and other partners and implemented by each country with technical assistance provided by 
ICF International. The DHS supports countries with standard methodologies, manuals, and 
procedures for data collection, including standard model survey questionnaires on 
population, nutrition, and health, and specific indicator surveys on HIV/AIDS and malaria. 
Data collection tools are tailored to fit the specific monitoring and evaluation needs of each 
country.
Materials and Methods
Two independent reviewers searched the DHS Program website by using the keywords 
breast cancer screening and cervical cancer screening to identify surveys that included these 
topics between the start of the DHS Program in 1984 and November 2015. Any differences 
in categorization were resolved collectively. Survey questionnaires were publicly available 
as final reports published on the DHS Program’s website. We downloaded the relevant 
surveys in English, French, Spanish, and Portuguese and carefully reviewed the sections on 
NCDs, healthcare utilization, and women’s health. The questionnaires were also searched by 
relevant keywords; the English search included the terms cancer, screening, cervix, vaginal, 
gynecologist, Papanicolau (Pap), Pap smear, mammogram, and breast. The questions related 
to cervical and breast cancers were extracted and translated into English if appropriate. They 
were grouped by themes of disease knowledge, screening knowledge, screening practice, 
and screening outcomes (Appendix 1). Descriptive statistics were compiled in an Excel 
worksheet to facilitate the quantitative and qualitative analyses of the data.
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Of the 90 countries where DHS surveys have been implemented, cervical cancer screening 
questions were included in 22 countries (24.4%) and breast cancer screening questions in 18 
countries (20.0%) (Fig. 2). The DHS Program website search returned 38 surveys from 22 
different countries conducted during 1985–2015 with questions related to cervical and breast 
cancer screening; 10 countries conducted more than 1 survey during this period (Appendix 
Table 1). Most of the surveys (30 of 38) asked about both cervical and breast cancers from18 
of 22 countries; 1 survey asked about only breast cancer; and 7 surveys asked just about 
cervical cancer from 6 of 22 different countries. In other words, nearly all (37 of 38) of these 
surveys included questions about cervical cancer from all 22 countries, and 31 of 38 surveys 
included questions about breast cancer from 18 of 22 countries.
Of those 38 surveys, 32 of the survey questionnaires were available to download from the 
website from 18 of the 22 different countries. Of the 32 available surveys, 25 of 32 asked 
about both cervical and breast cancers from 15 of 18 countries; 6 of 32 queried only cervical 
cancer from 5 of 18 countries; and 1 of 32 asked about only breast cancer from 1 of 18 
countries. In other words, nearly all (31 of 32) of these surveys included questions about 
cervical cancer from all 18 countries, and 26 of 32 surveys included questions about breast 
cancer from 16 of 18 countries.
Knowledge and awareness of cervical cancer disease were assessed in 8 of the 18 countries 
with surveys available for review (44.4%), and knowledge and awareness of cervical cancer 
screening were assessed in 6 of 18 different countries (33.3%) (Fig. 3). Three of the 16 
countries with surveys available for review (18.8%) asked about knowledge and awareness 
of breast cancer disease, and 7 countries (43.8%) asked about awareness and knowledge of 
breast cancer screening.
A history of screening for cervical cancer by using any modality, including general questions 
as well as those that specified Pap, cytology, or visual inspection methods, was asked in 12 
of 18 countries (66.7%). The timing and frequency of this testing were assessed in 12 
countries (66.7%). Four countries (22.2%) asked about cervical cancer screening location 
(i.e., clinic, hospital, private doctor), one country (5.6%) asked about cost, and two countries 
(11.1%) asked about barriers to screening. Eight countries (50.0%) assessed a history of 
screening for breast cancer, including mammography, clinical, and self-breast examination, 
and 11 countries (68.8%) asked questions about the timing of this screening. One country 
(6.3%) asked about location, cost, and barriers to screening. Five countries (27.8%) asked 
about receipt of results, and two of those countries (Bolivia and Colombia, 11.1%) assessed 
follow-up examinations, treatment, and barriers to treatment following cervical cancer 
screening. One country (Colombia, 6.3%) asked about receipt of results, follow-up 
examinations, barriers to follow-up, treatment, and barriers to treatment after breast cancer 
screening.
Cervical and breast cancer questions have been incorporated into relatively few DHS 
surveys, but their absolute inclusion has increased since 1984 (Fig. 4). Countries asked a 
wide range of questions to capture information about disease and screening knowledge, 
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practices, or outcomes. The most frequently assessed topics were whether the respondent 
had been screened for breast or cervical cancer and the timing or frequency of this screening. 
Relatively few countries asked specific questions about knowledge of disease and screening, 
and fewer assessed receipt of screening results, follow-up, and barriers.
Discussion
To guide national efforts to reduce the effects of cancers, surveys need to provide specific 
and measurable information about both the quantity and the quality of cancer screenings. 
More than half of the countries that asked cancer screening questions did include the core 
information to enable countries to document the prevalence of breast and cervical cancer 
screening. However, questions about follow-up and treatment of screened women were rare 
and missing a component of the screening process that is necessary to achieve reductions in 
cancer incidence and mortality. Very few surveys have incorporated these essential 
questions, which will enable countries to evaluate the effectiveness of their cancer screening 
practices beyond estimates of the proportion of eligible women screened.
On the basis of WHO global screening recommendations, countries that have determined 
their national cancer prevention and control priorities need specific information to evaluate 
the success of their interventions. Several DHS questionnaires in their current form provide 
information to assess the existence of breast or cervical cancer screening. Expansion of these 
questions by using the more comprehensive questionnaires as a model to include relevant 
knowledge, barriers, and follow-up could guide efforts to reduce the global burden of breast 
and cervical cancers.
A recent evaluation of the measurement of NCDs, including cancer, concluded that the DHS 
Program does collect useful information about NCDs.12 This year, DHS has made available 
to countries an optional NCD module with questions about overall cancer diagnoses as well 
as questions specific to cervical cancer screening. In addition, the WHO STEPS surveys 
currently include one question asking participants if they have ever been screened for 
cervical cancer.10 However, a prerequisite to the expansion of cancer screening data 
collection is careful evaluation of the relative utility of the data in terms of the increased 
costs. Collection of NCD data by the DHS may be more relevant among middle-income 
countries when compared with low-income countries.12 Of the 22 countries that asked 
questions about breast and cervical cancer screening in the DHS Program, most (19 of 22) 
are in the 2017 fiscal year World Bank middle-income categories.13 Middle-income 
countries may have more resources compared with low-income countries for implementing 
and monitoring screening programs. This disparity may explain the increased interest in 
cancer screening information and more comprehensive questionnaires in some of these 
middle-income countries, which could also provide guidance for standardized survey 
questions for the developing world. However, many low-income countries with high HIV 
prevalence also have initiated cervical cancer screening pilots, so this may be of interest to 
low-income countries as well.
The ability to assess the existence of cancer screening aligns with the most relevant WHO 
monitoring framework indicator—the proportion of eligible women screened for cervical 
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cancer. The WHO framework does not include indicators for breast cancer screening. The 
DHS surveys included in this review did not address the other WHO framework cancer 
indicators of availability of oncology medicines, treatment, palliation, incidence, and 
mortality. Cancer incidence and mortality may require the use of vital statistics systems, 
cancer registries, or other surveillance systems that monitor clinical care. There is a standard 
way to conduct vaccine coverage surveys, which several low- and middle-income countries 
are launching as part of their national immunization programs.14 HPV vaccine coverage is 
an essential piece of the cervical cancer prevention and control continuum, and countries 
that have implemented HPV vaccination can track this information at the country level.
The three common themes identified in this analysis (knowledge, practice, and outcomes) 
could guide the creation of a standard survey tool to be incorporated into future population-
based surveys. Such guidance would augment dissemination and comparability of 
population-level information about cervical and breast cancer screening, which would favor 
public health research at the global level and enable the monitoring and evaluation of 
national cancer control policies and programs, with the ultimate goal of reducing the burden 
of these cancers among low- and middle-income countries.
In response to the need for standardized cervical cancer survey questions, the CDC 
Foundation, in partnership with CDC, the George W. Bush Institute, and WHO, developed 
globally endorsed, population-based survey modules as part of the Improving Data for 
Decision Making in Global Cervical Cancer Programs (IDCCP) Toolkit, scheduled for 
global dissemination in 2017.15 The IDCCP Toolkit seeks to improve and accelerate the 
availability of data for cervical cancer program planning, monitoring, and evaluation. The 
population-based survey component of the Toolkit includes a core set of questions 
measuring cervical cancer screening coverage, screening interval, and follow-up and 
treatment of precancer, as well as an expanded module measuring knowledge and awareness, 
barriers and facilitators, screening location, single-visit approach, and HPV vaccination. To 
our knowledge, a similar initiative to create a tool kit to guide breast cancer screening has 
not yet been undertaken. Given the high burden of breast and cervical cancers among low- 
and middle-income countries, these initiatives are timely and critical.
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Appendix 1
Cervical and Breast Cancer Questions by Theme in the Demographic and 
Health Surveys
Cervical Cancer Knowledge and Awareness
Have you ever heard of cervical cancer?
Did you know anyone who died of cervical cancer?
How many women do you know who died of cervical cancer?
Did a health provider talk to you about cervical cancer?
Have you ever heard of the human papillomavirus?
Do you know what the human papillomavirus is?
Have you heard of a vaccine to prevent cervical cancer?
Cervical Cancer Screening Knowledge and Awareness
Have you ever heard of a Pap test?
Do you know what a Pap test is for?
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Do you know what vaginal cytology is?
Have you ever heard of vaginal cytology?
How did you learn about vaginal cytology?
In the last 12 months, have you received educational information about cervical cancer 
screening?
Cervical Cancer Screening Practice
Have you ever had a Pap test?
Have you ever had a gynecologic examination (not prenatal)?
Have you ever been screened for cervical cancer?
Have you ever had a vaginal cytology examination?
Have you ever had a cervical examination?
Has a health worker ever offered you a Pap smear?
What type of examination did you have to see if you have cervical cancer? PAP SMEAR, 
VIA, DON’T KNOW/NOT SURE
Cervical Cancer Screening (Frequency)
Have you had a Pap in the last 3 years?
How many times have you had a Pap in the last 3 years?
Have you had a gynecologic examination in the last 12 months?
Did your last gynecologic examination include a cancer prevention examination?
How many times have you had a vaginal cytology examination?
When was the last time you had a vaginal cytology examination?
How often have you had a vaginal cytology examination?
Have you had your last vaginal cytology examination more than 3 years ago?
In how long do you think you’ll have a new vaginal cytology examination?
Have you had a Pap in the last 12 months?
Have you had an examination for cervical cancer in the last 12 months?
When was the last time you had a Pap test?
Have you had a Pap test in the past 5 years?
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Cervical Cancer Screening (Location)
Where did you have your last gynecologic examination?
Where did you have a vaginal cytology examination the last time?
Where did you have your Pap test?
Cervical Cancer Screening (Barriers)
Why haven’t you ever had a vaginal cytology examination?
If you tried, why didn’t they give you a vaginal cytology examination?
Why didn’t you try to have a new vaginal cytology examination?
Why haven’t you ever had a Pap test?
Cervical Cancer Screening Results
What was the result of your Pap smear?
Did the result of your cancer prevention examination show a problem that needed treatment?
Did you get the results of your last vaginal cytology examination?
What was the result of your last vaginal cytology examination?
Why didn’t you get the results of your last vaginal cytology examination?
What did they tell you when they gave you the Pap test results?
How long had it been between your cytology and when you received the results?
Cervical Cancer Screening Follow-Up, Treatment, and Barriers
Did you need to have a colposcopy–biopsy because of abnormal cytology results?
As a result of your Pap test, did you have other examinations done?
As a result of your Pap test, did you follow-up with any treatment?
Did you have a follow-up visit for treatment?
Did you receive treatment as a result of the cytology or colposcopy–biopsy?
Why didn’t you go for a new visit?
Why didn’t you have a colposcopy–biopsy?
As a result of your Pap test, did you go to another health clinic?
Why didn’t you receive treatment?
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As a result of your Pap test, did you repeat the Pap test immediately or in the following 30 
days?
As a result of your Pap test, did you repeat the Pap test in 1 year or more?
Did you complete the recommended follow-up from your Pap test results? IF NO: Why not?
Breast Cancer Knowledge and Awareness
Have you ever heard of breast cancer?
What symptoms would make you think a woman has breast cancer?
Breast Cancer Screening Knowledge and Awareness
Have you ever heard of a mammogram or breast cancer screening?
Do you know what a breast self-examination is?
How did you learn how to do the breast self-examination?
Have you ever heard about mammography?
How did you learn about mammography?
Have you ever heard about a breast self-examination?
Do you know how to give yourself a breast examination?
At what moment of your menstrual cycle do you give yourself a breast self-examination?
Why did they give you a mammogram?
Why did they give you a clinical breast examination?
In the past 12 months, have you received educational information about breast cancer 
screening?
Do you know what a mammogram is?
Breast Cancer Screening Practice
Have you ever given yourself a breast examination?
Has a healthcare provider ever given you a breast examination?
Have you ever had a breast cancer screening?
Have you had a clinical breast examination?
Have you ever had a mammogram?
Do you self-examine your breasts?
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Where did you have your last mammogram?
Breast Cancer Screening (Frequency)
When was the last time you gave yourself a breast examination?
When was the last time a healthcare provider gave you a breast examination?
The last time a healthcare provider gave you a breast examination, what kind of a breast 
examination was it?
Did your last gynecological visit include a clinical breast examination?
How often do you give yourself a breast self-examination?
How long ago have you had a clinical breast examination?
When was the last time you had a mammogram?
How often do you have a mammogram?
In the past 12 months, have you had a breast cancer examination?
What type of breast cancer examination have you had in the past 12 months?
In the past 12 months, have you performed a breast cancer self-examination?
In the past 12 months, have you had a clinical breast cancer examination?
Have you had a clinical breast examination in the past 5 years?
Have you examined your breasts for any sign of a mass within the past month?
Breast Cancer Screening (Location)
Where did you have your last mammogram?
Breast Cancer Screening (Costs)
When you had a mammogram, did you have to pay for it?
Who covered the costs of your mammogram?
Was your last mammogram paid for by the institution you are affiliated with? Fully or 
partially?
Breast Cancer Screening (Barriers)
Why didn’t you have a mammogram?
Breast Cancer Screening Results
Was an abnormality or tumor detected during the clinical breast examination?
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Did you get the results of your last mammogram?
What was the result of your mammogram?
Breast Cancer Screening Follow-Up, Treatment, and Barriers
Did you have a biopsy as a result of an abnormal mammogram?
Why didn’t they give you a biopsy?
Why didn’t you get the results of your last mammogram?
As a result of the mammogram, did you go for a new visit for treatment?
Did you receive treatment as a result of your mammogram or biopsy?
Why didn’t you go for a new visit for treatment?
Why didn’t you receive treatment?
Appendix Table 1
Breast and Cervical Cancer Questions by Country in the Demographic and Health Surveys
Survey no. Country Survey year
Cancer
Contentb
  1 Albania 2008–2009 Both
  2 Armenia 2010 Both
  3 Armenia 2005 Both
  4 Armenia 2000 Both
  5 Bolivia 2008 Cervix
  6 Bolivia 2003 Cervix
  7 Brazil 1996 Both
  8 Brazil 1986 Cervix
  9 Burkina Faso 2010 Both
10a Colombia 2015 Both
11 Colombia 2010 Both
12 Colombia 2005 Both
13 Colombia 1990 Cervix
14 Cote d’Ivoire 2011–2012 Both
15 Dominican Republic 2013 Both
16 Dominican Republic 2007 Both
17a Egypt 2015 Both
18 Equatorial Guinea 2011 Both
19 Guatemala 1998–1999 Cervix
20 Honduras 2011–2012 Both
21 Honduras 2005–2006 Both
22a India 2014–2015 Both
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Survey no. Country Survey year
Cancer
Contentb
23 Jordan 2012 Both
24 Jordan 2007 Both
25 Jordan 2002 Breast
26a Kenya 2014 Both
27a Lesotho 2014 Both
28 Lesotho 2009 Both
29 Namibia 2013 Both
30 Peru 2013 Both
31 Peru 2011 Both
32 Peru 2010 Both
33 Peru 2009 Both
34 Philippines 2013 Both
35 Philippines 1998 Both
36 Tajikistan 2012 Both
37 Tanzania 2011–2012 Cervix
38a Zimbabwe 2015 Cervix
a
Survey questionnaire not available for download from DHS website at time of review.
b
Both refers to cervical and breast cancer questions.
DHS, Demographic and Health Surveys.
Viens et al. Page 13














In the context of a strong global commitment to reducing the high burden of cervical and 
breast cancers among low- and middle-income countries, strategies to improve screening 
are critical. This study identified gaps in the collection of screening data from population-
based surveys of breast and cervical cancer and identified themes that need to be included 
in a standardized survey tool to guide cancer control efforts in a comparable and effective 
manner.
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Countries that have conducted one or more Demographic and Health Surveys, 1984–2015.
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Questions about cervical and breast cancer screening in the Demographic and Health 
Surveys, 1984–2015.
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Number of countries that include breast and cervical cancer screening questions in their 
Demographic and Health Surveys by theme.
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Breast and cervical cancer screening questions in the Demographic and Health Surveys, 
survey count by year.
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